Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Disease mechanisms

Topic: Brain proteins, microglia and lab models

Plain-language summary

Cerebral deposition of amyloid beta peptide (Abeta) is an early and critical feature of Alzheimer's disease. Abeta generation depends on proteolytic cleavage of the amyloid precursor protein (APP) by two unknown proteases: beta-secretase and gamma-secretase. These proteases are prime therapeutic targets. A transmembrane aspartic protease with all the known characteristics of beta-secretase was cloned and characterized. Overexpression of this protease, termed BACE (for beta-site APP-cleaving enzyme) increased the amount of beta-secretase cleavage products, and these were cleaved exactly and only at known beta-secretase positions. Antisense inhibition of endogenous BACE messenger RNA decreased the amount of beta-secretase cleavage products, and purified BACE protein cleaved APP-derived substrates with the same sequence specificity as beta-secretase. Finally, the expression pattern and subcellular localization of BACE were consistent with that expected for beta-secretase. Future development of BACE inhibitors may prove beneficial for the treatment of Alzheimer's disease.

What this study adds

Evidence grade: Low

This study cloned and characterized BACE, an enzyme with the characteristics of beta-secretase, which cleaves amyloid precursor protein to produce amyloid beta peptide. It suggests that future development of BACE inhibitors may be beneficial for treating Alzheimer's disease, but no treatment was tested in people.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Vassar, R. J., Bennett, B. D., Babu‐Khan, S., Kahn, S., Mendiaz, E. A., Denis, P. E., et al. (1999). β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE. Science. https://doi.org/10.1126/science.286.5440.735

Vancouver

Vassar RJ, Bennett BD, Babu‐Khan S, Kahn S, Mendiaz EA, Denis PE, et al. β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE. Science. 1999. doi:10.1126/science.286.5440.735. PMID: 10531052.

BibTeX

@article{vassar1999-10531052,
  author  = {Vassar, Robert J. and Bennett, Brian D. and Babu‐Khan, Safura and Kahn, Steve and Mendiaz, Elizabeth A. and Denis, Paul E. and Teplow, David B. and Ross, Sandra L. and others},
  title   = {{β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE}},
  journal = {Science},
  year    = {1999},
  doi     = {10.1126/science.286.5440.735},
  pmid    = {10531052},
  url     = {https://doi.org/10.1126/science.286.5440.735}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study cloned and characterized BACE, an enzyme with the characteristics of beta-secretase, which cleaves amyloid precursor protein to produce amyloid beta peptide. It suggests that future development of BACE inhibitors may be beneficial for treating Alzheimer's disease, but no treatment was tested in people.

Study details

How this study scored 64/100
How this study's score is builtJournal tier 10 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 7 of 7; Citations per year 5 of 5; Impact for its field and year 6 of 6; Cited by studies here 5 of 6; Still being cited 4 of 4; Senior author's track record 3 of 4; Institution's track record 3 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 64 of 100.64 of 100 points earned36 not earned

Published in a top-tier journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 10 / 10 Tier 1 — top-tier general journal (Science)
Journal's citation record 4 / 4 Science: journal h-index 1,754 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 1999 — older than 20 years, still counted
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 7 / 7 Cited 3,879 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 133.8 citations a year over 29 year(s) since 1999
Impact for its field and year 6 / 6 Cited 84.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 5 / 6 Cited by 106 other studies in this library
Still being cited 4 / 4 Cited 249 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Martin Citron: h-index 56 (OpenAlex, whole career)
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 10531052)
Free to read 2 / 2 Free to read
Total 64 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

106 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Disease mechanisms from nearby years

Also tagged “precursor”

1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Disease mechanisms

See all studies in Disease mechanisms →